GREENWICH, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced the completion of its inaugural European bond offering, with its wholly owned subsidiary GXO Logistics Capital B.V. issuing €500m in senior unsecured notes (the “notes”). The notes will bear interest at a rate of 3.750% per annum payable annually, commencing November 24, 2026, and will mature on November 24, 2030. “The successful close of our first ...

Third Quarter Presentation Nov 2025 Forward Looking Statements MATTERS DISCUSSED IN THIS DOCUMENT MAY CONSTITUTE FORWARD-LOOKING STATEMENTS. THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES SAFE HARBOR PROTECTIONS FOR FORWARD-LOOKING STATEMENTS IN ORDER TO ENCOURAGE COMPANIES TO PROVIDE PROSPECTIVE INFORMATION ABOUT THEIR BUSINESS. FORWARD-LOOKING STATEMENTS INCLUDE STATEMENTS CONCERNING PLANS, OBJECTIVES, GOALS, STRATEGIES, FUTURE EVENTS OR PERFORMANCE, AND UNDERLYING ASSUMPTIONS AND OTHER STA ...

Financial Highlights - System-wide store sales reached $3.5 billion, an increase of 11%[8] - Net sales were $1.7 billion, up by 12%[8] - Adjusted EBITDA was $467 million, reflecting an increase of 11%[10] - Adjusted EPS was $1.59[12] Store Network Growth - Net store additions totaled 170[11] - System locations reached 2,180, an increase of 8%[13] Same Store Sales Growth - System-wide same store sales growth was 6.1%[9] FY2026 Guidance (Includes Breeze) - System-wide same store sales growth is projected to be between 4% and 6%[58] - Net revenues are expected to range from $2.0 billion to $2.1 billion[58] - Adjusted EBITDA is forecasted to be between $525 million and $550 million[58] Balance Sheet - Cash and cash equivalents totaled $51.6 million[53] - Total debt amounted to $1.074 billion[53] Cash Flow - Cash flows from operating activities were $307.1 million[55] - Capital expenditures totaled $259.2 million[55]

Core Points - Diversified Energy Company has received approval from the Financial Conduct Authority (FCA) for its prospectus dated November 19, 2025, related to the admission of its ordinary shares to the Official List and trading on the London Stock Exchange [2] - The prospectus will be available on the company's website and submitted to the National Storage Mechanism, with the scheme expected to become effective around November 21, 2025, and shares anticipated to be listed on the NYSE by November 24, 2025 [3] Company Overview - Diversified Energy Company is a publicly traded energy firm focused on acquiring, operating, and optimizing cash-generating energy assets, recognized for its sustainability leadership [4] - The company employs a differentiated strategy to acquire long-life assets, investing in them to enhance environmental and operational performance before safely retiring them [4]

FORT WORTH, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the Piper Sandler 37th Annual Healthcare Conference, which is being held at The Lotte New York Palace in New York, NY from December 2 – 4, 2 ...

Accessibility StatementSkip Navigation ALLENTOWN, Pa., Nov. 19, 2025 /PRNewswire/ -- PPL Capital Funding, Inc. ("PPL Capital Funding"), a wholly-owned subsidiary of PPL Corporation (NYSE: PPL), announced today that it intends to offer, subject to market conditions and other factors, $1 billion aggregate principal amount of its Exchangeable Senior Notes due 2030 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A unde ...

Core Insights - Protara Therapeutics, Inc. is hosting a conference call on November 19, 2025, to discuss new data from the interim analysis of the Phase 2 STARBORN-1 trial for TARA-002, a cell-based therapy for pediatric patients with lymphatic malformations [1][2] Group 1: Company Overview - Protara Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases [5] - The company's lead candidate, TARA-002, is in development for non-muscle invasive bladder cancer and lymphatic malformations [5] - TARA-002 has received Rare Pediatric Disease designation from the U.S. FDA for the treatment of lymphatic malformations [3] Group 2: Product Details - TARA-002 is a genetically distinct strain of streptococcus pyogenes that retains immune-stimulating properties while being inactivated [3] - The therapy was developed from the same master cell banks as OK-432, which has been the standard of care in Japan for 30 years [3] - A large Phase 2 trial of OK-432 demonstrated significant clinical success in over 500 patients with lymphatic malformations [3] Group 3: Lymphatic Malformations - Lymphatic malformations are rare congenital conditions affecting lymphatic vessels, often diagnosed in early childhood [4] - More than 50% of lymphatic malformations are detected at birth, with 90% diagnosed before the age of three [4] - Common complications include airway obstruction, intralesional bleeding, and recurrent infections, leading to significant morbidity [4]

SLINGERLANDS, N.Y., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (“Plug Power”) (NASDAQ: PLUG) today announced its intention to offer, subject to market conditions and other factors, $375 million aggregate principal amount of Convertible Senior Notes due 2033 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Plug Power also expects to grant the initial purchaser of the notes a ...

Fourth Quarter 2025 Forward Looking Statements & Legal Disclosures Some of the statements in this presentation constitute forward-looking statements because they relate to future events or our future performance or financial condition. The forward-looking statements contained in this presentation may include statements as to: our future operating results and distribution projections; the ability of Oaktree Fund Advisors, LLC (together with its affiliates, "Oaktree") to implement Oaktree's future plans with ...

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Galleon Gold Corp. (TSXV: GGO) (FSE: 3H90) (the "Company" or "Galleon Gold") announces that under the terms of the convertible debentures (the "Convertible Debentures") issued on April 12, 2024, April 19, 2024 and April 29, 2024 (see news releases dated April 12, 19, and 29, 2024) it has elected to satisfy its obligation to pay interest accrued by issuing common shares (the "Common Shares").Under the terms of the Convertible Debentures, no fractional ...